Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weider marketing plans

This article was originally published in The Tan Sheet

Executive Summary

October print ads will support launch of Schiff Prostate Health, relaunch of Breast Health, supplement firm says Sept. 26 in announcing fiscal first quarter financial results. Hitting shelves by early December, Prostate Health contains lycopene, saw palmetto, calcium d-glucarate, while Breast Health features calcium d-glucarate, soy isoflavones, antioxidants. One-month supply of each will retail for $15, firm says. Weider plans to "significantly ramp up" marketing spending for Schiff line in mid-Q2. Net sales for division were up 1.5% to $41.2 mil. due to greater sales incentives, promotions, firm notes. Move Free line sales decreased 4.6% to $18.7 mil. due to private label competition. Move Free Triple Strength, which offers same amount of glucosamine/chondroitin in two tablets rather than three, debuted in late summer and is expanding distribution, Weider notes...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel